01.15.15
Dr. Jeff Golini’s latest research article, "Buffered Vs. Non-Buffered Aliphatic Fatty Acids And Their Anti-Proliferative Effects In Human Tumor Cell Lines,” has been accepted by the Single Cell Biology Journal for publication. Two other research articles authored by Dr. Golini have also appeared in other peer-reviewed journals.
The Single Cell Biology Journal strives to publish groundbreaking research in combined disciplines and will only accept scholarly articles after completing a full peer-review process. Publication of the articles represents another major step forward for Dr. Golini and All American Pharmaceutical, a high-end contract manufacturing and research facility that specializes in producing innovative health-based ingredients and sports nutrition products.
"At All American Pharmaceutical, our in-house R&D is in a constant state of evolution," notes Dr. Golini, who serves as executive scientist for the company. "Any product we design is backed by IRB sanctioned research data before it reaches the market. Since our first Orphan Drug designation, we've been ramping up and branching out steadily into new health-related sectors. In 2015, our product lines are being positioned to expand rapidly, as is our in-house research interests and goals."
For more information: www.allamph.com
The Single Cell Biology Journal strives to publish groundbreaking research in combined disciplines and will only accept scholarly articles after completing a full peer-review process. Publication of the articles represents another major step forward for Dr. Golini and All American Pharmaceutical, a high-end contract manufacturing and research facility that specializes in producing innovative health-based ingredients and sports nutrition products.
"At All American Pharmaceutical, our in-house R&D is in a constant state of evolution," notes Dr. Golini, who serves as executive scientist for the company. "Any product we design is backed by IRB sanctioned research data before it reaches the market. Since our first Orphan Drug designation, we've been ramping up and branching out steadily into new health-related sectors. In 2015, our product lines are being positioned to expand rapidly, as is our in-house research interests and goals."
For more information: www.allamph.com
